Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.

Autor: Elena G Kamburova, Hans J P M Koenen, Martijn W F van den Hoogen, Marije C Baas, Irma Joosten, Luuk B Hilbrands

Publikováno v: PLoS ONE, Vol 9, Iss 11, p e112658 (2014)

Prevention of rejection after renal transplantation requires treatment with immunosuppressive drugs. Data on their in vivo effects on T- and B-cell phenotype and function are limited.In a randomized double-blind placebo-controlled study to prevent re

Externí odkaz: https://doaj.org/article/804f77fa801a49138c380ea6cd75f0ba

Comparison of alemtuzumab and anti-thymocyte globulin treatment for acute kidney allograft rejection

Autor: Marieke van der Zwan, Marian C. Clahsen-Van Groningen, Martijn W. F. van den Hoogen, Marcia M. L. Kho, Joke I. Roodnat, Katya A. L. Mauff, Dave L. Roelen, Madelon van Agteren, Carla C. Baan, Dennis A. Hesselink

Publikováno v: Frontiers in Immunology, 11:1332. Frontiers Media S.A.
Frontiers in Immunology, Vol 11 (2020)
Frontiers in Immunology, 11. FRONTIERS MEDIA SA
Frontiers in Immunology

Rabbit anti-thymocyte globulin (rATG) is currently the treatment of choice for glucocorticoid-resistant, recurrent, or severe acute allograft rejection (AR). However, rATG is associated with severe infusion-related side effects. Alemtuzumab is incide

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80e9dd4fb381dee683b0eb234bdaf239
https://hdl.handle.net/1887/3182812